Development and optimization of curcumin-loaded mannosylated chitosan nanoparticles using response surface methodology in the treatment of visceral leishmaniasis

Expert Opinion on Drug Delivery

Volumn 11, Issue 8, 2014, Pages 1163-1181

  Chaubey, Pramila ^a   Patel, Ravi R ^a   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Central composite design; Curcumin; Nanoparticles; Optimization; Response surface methodology; Visceral leishmaniasis

Indexed keywords

CHITOSAN DERIVATIVE; CURCUMIN; LIPOSOME; MANNOSE; MANNOSYLATED CHITOSAN NANOPARTICLE; MICROSPHERE; NANOPARTICLE; UNCLASSIFIED DRUG;

AMINATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ATOMIC FORCE MICROSCOPY; CONJUGATE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NONHUMAN; ORGAN DISTRIBUTION; PARTICLE SIZE; PERITONEUM MACROPHAGE; RAT; RESPONSE SURFACE METHOD; RETICULOENDOTHELIAL SYSTEM; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE PREPARATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCERAL LEISHMANIASIS; X RAY DIFFRACTION; ZETA POTENTIAL;

CENTRAL COMPOSITE DESIGN; CURCUMIN; NANOPARTICLES; OPTIMIZATION; RESPONSE SURFACE METHODOLOGY; VISCERAL LEISHMANIASIS;

ANIMALS; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CURCUMIN; DRUG CARRIERS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; LEISHMANIASIS, VISCERAL; MALE; MANNOSE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES;

EID: 84904707307     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.917076     Document Type: Article

References (44)

1. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:356-71
2. Murray WH. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004;71:787-94
3. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005;26:7260-75
4. Yeeprae W, Kawakami S, Yamashita F, Hashida M. Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated o/w emulsions by macrophages. J Control Release 2006;114:193-201
5. Wadhwa MS, Rice KG. Receptor mediated glycotargeting. J Drug Target 2003;11:255-68
6. Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-Targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 2008;6:703-24
7. Vyas SP. Macrophage targeting and colloidal drug carriers. In: Vyas SP, Dixit VK, editors. Advances in liposomal research. CBS Publishers and Distributors, New Delhi; 2000. p. 98-120
8. Bachhawat BK, Das PK, Ghosh PK. Preparation of glycosides bearing liposomes for targeting. In: Gregoriadis G, editor. Liposome technology. CRC Press, Boca Raton, FL; 1984. p. 117-38
9. Garcon N, Gregoriadis G, Taylor M, Summerfield J. Mannose mediated targeted immunoadjuvant action of liposomes. Immunology 1988;64:743-8
10. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010;343:489-99
11. Das R, Roy A, Dutta N, Majumder HK. Reactive oxygen species and imbalance of calcium homeostasis contributes to curcumin induced programmed cell death in Leishmania donovani. Apoptosis 2008;13:867-82
12. Saleheen D, Ali SA, Ashfaq K, et al. Latent activity of curcumin against leishmaniasis in vitro. Biol Pharm Bull 2002;25:386-9
13. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001;21:2895-900
14. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-54
15. Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm 2002;244:127-35
16. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4:807-18
17. Rinaudo M. Chitin and chitosan: Properties and applications. Prog Polym Sci 2006;31:603-32
18. Chaubey P, Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydr Polym 2014;101:1101-8
19. Zhang J, Tang Q, Xu X, Li N. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery. Int J Pharm 2013;448:168-74
20. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." Part I: Fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005;22:27-105
21. Leardi R. Experimental design in chemistry: A tutorial. Anal Chim Acta 2009;652:161-72
22. Hibbert DB. Experimental design in chromatography: A tutorial review. J Chromatogr B Analyt Technol Biomed Life Sci 2012;910:2-13
23. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnology 2007;5:3
24. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009;29:3867-75
25. Reddy LH, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004;148:161-6
26. Gulyaev AE, Gelperina SE, Skidan IN, et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999;16:1564-9
27. Karki R, Subramanya G, Udupa N. Formulation and evaluation of coencapsulated rifampicin and isoniazid liposomes using different lipids. Acta Pharma Sci 2009;51:177-88
28. Tiwari S, Chaturvedi AP, Tripathi YB, Mishra B. Macrophage specific targeting of isoniazid through mannosylated gelatin microspheres. AAPS PharmSci Tech 2011;12:900-8
29. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharmacol 2005;2:373-83
30. Manandhar KD, Yadav TP, Prajapati VK, et al. Antileishmanial activity of nano-Amphotericin B deoxycholate. J Antimicrob Chemother 2008;62:376-80
31. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31-48
32. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly(,-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002;82:105-14
33. Chakraborty S, Shukla D, Vuddanda PR, et al. Utilization of adsorption technique in the development of oral delivery system of lipid based nanoparticles. Colloids Surf B Biointerfaces 2010;81:563-9
34. Wisse E, Leeuw AM. Structural elements determining transport and exchange process in the liver. In: Davis SS, Illum L, McVie JG, Tomlinson E, editors. Microspheres and drug therapy, pharmaceutical, immunological and medical aspects. Elsevier, Amsterdam; 1984. p. 1-23
35. Gonzalez-Mira E, Egea MA, Souto EB, et al. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011;22:1-15
36. Holzer M, Vogel V, Mäntele W, et al. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm 2009;72:428-37
37. Chono S, Tanino T, Seki T, Morimoto K. Uptake characteristics of liposomes by rat alveolar macrophages: Influence of particle size and surface mannose modification. J Pharm Pharmacol 2007;59:75-80
38. Douglas SJ, Illum L, Davis SS, Kreuter J. Particle size and size distribution of poly (butyl-2-cyanoacrylate) nanoparticles. J Colloid Interface Sci 1984;101:149-58
39. Chiannilkulchai N, Ammoury N, Caillou B, et al. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. administration in reticulosarcoma M5076 metastasesbearing mice. Cancer Chemother Pharmacol 1990;26:122-6
40. Kunwar A, Barik A, Mishra B, et al. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochem Biophys Acta 2008;1780:673-9
41. Kim TH, Jiang HH, Youn YS, et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011;403:285-91
42. Lankveld DP, Oomen AG, Krystek P, et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials 2010;31(32):8350-61
43. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010;79:330-8
44. Rittig MG, Bogdan C. Leishmania-host-cell interaction: Complexities and alternative views. Parasitol Today 2000;16:292-7.